Table 3.
Association tests of PNPLA3 rs1010023 with hepatic steatosis.
| Group | OR (95% CI) | P value | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Normal | HS | CHB | CHB+HS | Unadjusted | Adjusted for age, gender | Adjusted for age, gender, BMI | Unadjusted | Adjusted for age, gender | Adjusted for age, gender, BMI | |
| Normal versus CHB | C: 16.67% T: 83.33% |
C: 24.49% T: 75.51% |
1.310 (0.647–2.654) |
1.356 (0.695–2.643) |
1.315 (0.674–2.567) |
0.453 | 0.372 | 0.422 | ||
| Normal versus HS | C: 16.67% T: 83.33% |
C: 32.43% T: 67.57% |
2.302 (1.216–4.358) |
2.679 (1.348–5.323) |
3.460 (1.209–9.904) |
0.010 | 0.005 | 0.021 | ||
| Normal versus CHB+HS | C: 16.67% T: 83.33% |
C: 37.04% T: 62.96% |
2.048 (1.182–3.550) |
2.529 (1.335–4.792) |
3.018 (1.318–6.914) |
0.011 | 0.004 | 0.009 | ||
| CHB versus HS | C: 32.43% T: 67.57% |
C: 24.49% T: 75.51% |
2.401 (1.264–4.561) |
2.334 (1.169–4.657) |
2.774 (1.176–6.543) |
0.007 | 0.016 | 0.020 | ||
| CHB versus CHB+HS | C: 24.49% T: 75.51% |
C: 37.04% T: 62.96% |
1.781 (1.046–3.033) |
2.170 (1.128–4.174) |
1.768 (1.027–3.105) |
0.034 | 0.020 | 0.045 | ||
| HS versus CHB+HS | C: 32.43% T: 67.57% |
C: 37.04% T: 62.96% |
1.298 (0.714–2.359) |
1.347 (0.689–2.816) |
1.265 (0.705–2.433) |
0.392 | 0.488 | 0.421 | ||
BMI: body mass index; CHB: chronic hepatitis B; CI: confidence interval; HS: hepatic steatosis; OR: odds ratio; SNPs: single nucleotide polymorphisms.